SPPI Share Price

Open 4.23 Change Price %
High 4.56 1 Day 0.28 6.73
Low 4.17 1 Week 0.44 11.00
Close 4.44 1 Month 0.23 5.46
Volume 958661 1 Year -1.22 -21.55
52 Week High 7.74
52 Week Low 3.21
SPPI Important Levels
Resistance 2 4.80
Resistance 1 4.65
Pivot 4.39
Support 1 4.23
Support 2 4.08
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ETRM 0.07 0.00%
AAPL 113.86 1.55%
AAPL 113.86 1.55%
More..
NASDAQ USA Top Gainers Stocks
HTCO 11.00 62.96%
LOCM 0.09 50.00%
OPXA 1.21 40.70%
QKLS 0.18 38.46%
ZAZA 0.08 33.33%
MOSY 0.46 31.43%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PPHM 0.40 25.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
BGMD 0.05 -37.50%
More..

Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI)

SPPI Technical Analysis 1.5
As on 9th Dec 2016 SPPI Share Price closed @ 4.44 and we RECOMMEND Sell for LONG-TERM with Stoploss of 5.65 & Buy for SHORT-TERM with Stoploss of 4.17 we also expect STOCK to react on Following IMPORTANT LEVELS.
SPPI Target for December
1st Target up-side 4.79
2nd Target up-side 5.39
3rd Target up-side 6
1st Target down-side 3.05
2nd Target down-side 2.45
3rd Target down-side 1.84
SPPI Other Details
Segment EQ
Market Capital 683767552.00
Sector Consumer Durables Major Pharmaceuticals
Industry
Offical website
SPPI Address
SPPI
N/A
Interactive Technical Analysis Chart Spectrum Pharmaceuticals, Inc. ( SPPI NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Spectrum Pharmaceuticals, Inc.
SPPI Business Profile
Spectrum Pharmaceuticals, Inc. (Spectrum) is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology. In the United States, the Company markets three oncology drugs, FUSILEV, FOLOTYN and ZEVALIN and also markets ZEVALIN outside of the United States, it has two drugs, apaziquone and belinostat, in late stage development along with a diversified pipeline of drug candidates.Apaziquone is studied in two Phase III clinical trials for non-muscle invasive bladder cancer, or NMIBC, and is under strategic collaborations with Nippon Kayaku Co. Ltd.(Nippon Kayaku), and Handok Pharmaceuticals Co. Ltd. (Handok). Belinostat, is being studied in multiple indications including a Phase II registrational trial for relapsed or refractory peripheral T-cell lymphoma (PTCL), under a strategic collaboration with TopoTarget A/S (TopoTarget). On September 5, 2012, it acquired Allos Therapeutics, Inc.